Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice | Breast Cancer Research | Full Text
Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer | npj Breast Cancer
Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer
Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer | npj Breast Cancer
Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm - Boyle - 2018 - Asia-Pacific Journal of Clinical Oncology - Wiley Online Library
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - The Breast
Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole ...
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Presentación de PowerPoint
PDF) Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)
Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole ...
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study ...
Japanese patients in PALOMA-2: swimmer plot of subsequent therapy in... | Download Scientific Diagram
Progression-free survival in the PALOMA-1 study (palbociclib +... | Download Scientific Diagram
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up | SpringerLink
Palbociclib and Letrozole in Advanced Breast Cancer | NEJM
Final analysis of progression-free survival in the PALOMA-3 study... | Download Scientific Diagram
IBRANCE 75 mg hard capsules - Summary of Product Characteristics (SmPC) - (emc)
Palbociclib plus endocrine therapy in older women with HR+/HER2– advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies - ScienceDirect
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
IJMS | Free Full-Text | Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis | HTML
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases - ScienceDirect
Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3 | SpringerLink
Figure 2 from Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18
